


- 28 -

CLAIMS

1. An indazolamide of formula I:



5

wherein

X is an NHC(O) or C(O)NH group,

- R1 is a hydrogen or halogen atom, or an aminocarbonyl, acetylamino, sulphonylmethyl, aminosulphonylmethyl, linear or
 10 branched C₁₋₃ alkyl or C₁₋₃ alkoxy group,
 R2 is a hydrogen atom or a linear or branched C₁₋₆ alkyl group or an aryl(C₁₋₃)alkyl group in which the abovementioned groups are optionally substituted with one or more substituents chosen from the group comprising halogen atoms, C₁₋₃ alkyl and C₁₋₃ alkoxy,
 15 R3 and R4, which may be identical or different, are a hydrogen or halogen atom, or an amino, nitro, hydroxyl, linear or branched C₁₋₃ alkyl, C₁₋₃ alkoxy, di(C₁₋₃)alkylamino, acetylamino or O-(C₁₋₃)alkylphenyl group, or R3 and R4, together, form a 5- to 7-membered ring in which one or two of the said members may be a
 20 hetero atom chosen from N, S and O,
 R5, R6, R7 and R8, which may be identical or different, are H or methyl;
 and acid-addition salts thereof with pharmaceutically acceptable organic and mineral acids.
- 25 2. An indazolamide according to Claim 1, characterized in that R1 is H, methyl or methoxy.


- 29 -

3. An indazolamide according to Claim 1 or 2, characterized in that R2 is H, methyl or isopropyl.
4. An indazolamide according to any one of Claims 1 to 3, characterized in that R3 is H, methyl, hydroxyl, amino or
5 dimethylamino.
5. An indazolamide according to any one of Claims 1 to 4, characterized in that R4 is H, methyl or hydroxyl.
6. An indazolamide according to any one of Claims 1 to 5, characterized in that R5, R6, R7 and R8 are H.
- 10 7. An indazolamide according to any one of Claims 1 to 6, characterized in that it is a salt of addition of a pharmaceutically acceptable acid chosen from the group comprising oxalic acid, maleic acid, succinic acid, citric acid, tartaric acid, lactic acid, methanesulphonic acid, para-toluenesulphonic acid, hydrochloric
15 acid, phosphoric acid and sulphuric acid.
8. N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
9. Hydrochloride salt of the compound of the preceding Claim 8.
- 20 10. N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
11. Tosylate salt of the compound of the preceding Claim 10.
12. N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1-benzyl-
25 1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
13. Hydrochloride salt of the compound of the preceding Claim 12.
14. N3-((1-(2-Oxo-2-((4-((phenylmethyl)oxy)phenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and
30 pharmaceutically acceptable acid-addition salts thereof.

- 30 -

15. N3-((1-(2-((4-Hydroxyphenyl)amino)-2-oxoethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
16. Hydrochloride salt of the compound of the preceding Claim 15.
- 5 17. N3-((1-(2-Oxo-2-((4-nitrophenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
18. N3-((1-(2-Oxo-2-((4-aminophenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically
- 10 acceptable acid-addition salts thereof.
19. Dihydrochloride salt of the compound of the preceding Claim 18.
20. 5-Methyl-N3-((1-(2-oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
- 15 21. Hydrochloride salt of the compound of the preceding Claim 20.
22. 5-Methyl-N3-((1-(2-oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
23. Hydrochloride salt of the compound of the preceding Claim 22.
- 20 24. N3-((1-(2-Oxo-2-((4-(dimethylamino)phenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and pharmaceutically acceptable acid-addition salts thereof.
25. Dihydrochloride salt of the compound of the preceding Claim 24.
26. N3-((1-(2-Oxo-2-((2,6-dimethylphenyl)amino)ethyl)-4-piperidyl)methyl)-1-(1-methylethyl)-1H-indazole-3-carboxamide and
- 25 pharmaceutically acceptable acid-addition salts thereof.
27. Oxalate salt of the compound of the preceding Claim 26.
28. A process for preparing an indazolamide of formula I:

- 31 -



(I)

wherein

X is an NHC(O) or C(O)NH group,

5 R1 is a hydrogen or halogen atom, or an aminocarbonyl, acetylamino, sulphonylmethyl, aminosulphonylmethyl, linear or branched C₁₋₃ alkyl or C₁₋₃ alkoxy group,

10 R2 is a hydrogen atom or a linear or branched C₁₋₆ alkyl group or an aryl(C₁₋₃)alkyl group in which the abovementioned groups are optionally substituted with one or more substituents chosen from the group comprising halogen atoms, C₁₋₃ alkyl and C₁₋₃ alkoxy,

15 R3 and R4, which may be identical or different, are a hydrogen or halogen atom, or an amino, nitro, hydroxyl, linear or branched C₁₋₃ alkyl, C₁₋₃ alkoxy, di(C₁₋₃)alkylamino, acetylamino or O-(C₁₋₃)alkylphenyl group, or R3 and R4, together, form a 5- to 7-membered ring in which one or two of the said members may be a hetero atom chosen from N, S and O,


R5, R6, R7 and R8, which may be identical or different, are H or methyl;

20 and acid-addition salts thereof with pharmaceutically acceptable organic and mineral acids,

characterized in that it comprises the following stages:

a) condensing an amine of formula (II)

- 32 -




(II)

in which

X, R3, R4, R5, R6, R7 and R8 have the meanings given above,

5 with an indazolecarboxylic acid derivative of formula (IIIa)



(IIIa)

in which


10 R1 and R2 have the meanings given above, and

Y is a chlorine or bromine atom, or a group OR or OC(O)R, in which

R is an alkyl with a linear or branched chain containing from 1 to 6 carbon atoms,

or of formula (IIIb)

15



(IIIb)

in which


R1 has the meanings given above,

20

to give the indazolamide of formula (I), and

- 33 -

- b) optionally, forming an acid-addition salt of the indazolamide of formula (I) with a pharmaceutically acceptable organic or mineral acid.
29. A process according to Claim 28, characterized in that stage (a) is performed by reacting a compound of formula (II) with a compound of formula (IIIa) in which Y is chlorine or with a compound of formula (IIIb) in the presence of a suitable diluent at a temperature in the range between 0 and 140°C for a time of between 0.5 and 20 hours.
30. A process according to Claim 29, characterized in that the reaction temperature is in the range between 15 and 40°C.
31. A process according to Claim 29, characterized in that the reaction time ranges from 1 to 14 hours.
32. A process according to any one of Claims 28 to 31, characterized in that the diluent is aprotic.
33. A process according to Claim 32, characterized in that the diluent is an aprotic apolar diluent.
34. A process according to any one of Claims 28 to 33, characterized in that when Y is chlorine or bromine, the abovementioned stage a) is performed in the presence of an organic or mineral acid acceptor.
35. A pharmaceutical composition containing an effective amount of a compound of formula (I):




wherein

- 25 X is an NHC(O) or C(O)NH group,

- 34 -

- R1 is a hydrogen or halogen atom, or an aminocarbonyl, acetylamino, sulphonylmethyl, aminosulphonylmethyl, linear or branched C₁₋₃ alkyl or C₁₋₃ alkoxy group,
- R2 is a hydrogen atom or a linear or branched C₁₋₆ alkyl group or an aryl(C₁₋₃)alkyl group in which the abovementioned groups are optionally substituted with one or more substituents chosen from the group comprising halogen atoms, C₁₋₃ alkyl and C₁₋₃ alkoxy,
- R3 and R4, which may be identical or different, are a hydrogen or halogen atom, or an amino, nitro, hydroxyl, linear or branched C₁₋₃ alkyl, C₁₋₃ alkoxy, di(C₁₋₃)alkylamino, acetylamino or O-(C₁₋₃)alkylphenyl group, or R3 and R4, together, form a 5- to 7-membered ring in which one or two of the said members may be a hetero atom chosen from N, S and O,
- R5, R6, R7 and R8, which may be identical or different, are H or methyl;
- or of an acid-addition salt thereof with a pharmaceutically acceptable acid, and
- at least one pharmaceutically acceptable inert ingredient.

36. An intermediate of formula (II)



(II)

wherein

- X is an NHC(O) or C(O)NH group,
- R3 and R4, which may be identical or different, are a hydrogen or halogen atom, or an amino, nitro, hydroxyl, linear or branched C₁₋₃

- 35 -

alkyl, C₁₋₃ alkoxy, di(C₁₋₃)alkylamino, acetylamino or
O-(C₁₋₃)alkylphenyl group, or R3 and R4, together, form a 5- to 7-
membered ring in which one or two of the said members may be a
hetero atom chosen from N, S and O,

5 R5, R6, R7 and R8, which may be identical or different, are H or
methyl.

37. An amine according to Claim 35, characterized in that R3 is H,
methyl, hydroxyl, benzyloxy, nitro, amino or dimethylamino.

38. An amine according to Claim 35, characterized in that R4 is H or
10 methyl.

39. An amine according to Claim 35, characterized in that R5, R6, R7
and R8 are H.